Literature DB >> 6538750

Lack of age-dependent cisplatin nephrotoxicity.

W J Hrushesky, W Shimp, B J Kennedy.   

Abstract

Cisplatin nephrotoxicity was evaluated by serial pretreatment and post-treatment 24-hour creatinine clearance determinations in 43 patients who received 295 monthly infusions of 60 mg/m2 of this drug. An aggressive standard hydration protocol was used without diuretic administration. Fourteen of these patients had a single kidney. Older patients and patients with a single kidney had lower pretreatment creatinine clearances when compared with younger persons with two functioning kidneys. Older and younger patients with two kidneys had an equal, progressive, dose-related deterioration of renal function. Renal function did not decline in persons with a single kidney but did so markedly in those with two kidneys. When administered at 60 mg/m2, cisplatin dose or schedule modification is not indicated on the basis of advancing age or decreased renal function secondary to the surgical loss or total ureteral obstruction of one kidney.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538750     DOI: 10.1016/0002-9343(84)90280-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  24 in total

Review 1.  Pharmacology of anticancer drugs in the elderly population.

Authors:  Hans Wildiers; Martin S Highley; Ernst A de Bruijn; Allan T van Oosterom
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  [Oncologic pharmacotherapy of elderly patients].

Authors:  U Wedding; U Merkel; K Farker; K Höffken
Journal:  Internist (Berl)       Date:  2003-08       Impact factor: 0.743

3.  Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a Cancer and Leukemia Group B study.

Authors:  J B Hargis; J R Anderson; K J Propert; M R Green; D A Van Echo; R B Weiss
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Cisplatin nephrotoxicity as a model of chronic kidney disease.

Authors:  Mingjun Shi; Kathryn L McMillan; Junxia Wu; Nancy Gillings; Brianna Flores; Orson W Moe; Ming Chang Hu
Journal:  Lab Invest       Date:  2018-06-01       Impact factor: 5.662

5.  Experimental verification of age-dependent cisplatin-induced nephrotoxicity in rats using dynamic contrast-enhanced computed tomography.

Authors:  Atsushi Tachibana; Ayumu Nagasawa; Akihiro Kitamura; Shohei Miyazaki; Kenya Murase
Journal:  Jpn J Radiol       Date:  2010-02-26       Impact factor: 2.374

Review 6.  Distal convoluted tubule.

Authors:  James A McCormick; David H Ellison
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

7.  Moderate aging does not exacerbate cisplatin-induced kidney injury or fibrosis despite altered inflammatory cytokine expression and immune cell infiltration.

Authors:  Cierra N Sharp; Mark Doll; Tess V Dupre; Levi J Beverly; Leah J Siskind
Journal:  Am J Physiol Renal Physiol       Date:  2018-11-28

Review 8.  Problems in the use of anticancer drugs in the elderly.

Authors:  J E Phister; S G Jue; B J Cusack
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

9.  Renal function, serum calcium and magnesium during treatment of advanced bladder carcinoma with cis-dichlorodiamineplatinum: impact of tumour site, patient age and magnesium suppletion.

Authors:  J H Blom; K H Kurth; T A Splinter
Journal:  Int Urol Nephrol       Date:  1985       Impact factor: 2.370

10.  Long-term studies of cisplatin-induced reductions in porcine renal functional reserve.

Authors:  M E Robbins; T B Bywaters; R S Jaenke; J W Hopewell; L M Matheson; P Tothill; E Whitehouse
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.